Global Paediatric Vaccine Market - Forecasts From 2018 to 2023
The global paediatric Vaccine market is expected to reach US$42.865 billion by 2023 from US$21.144 billion in 2017 growing at a CAGR of 12.50%. Vaccination and immunization of children are essential component of modern medicine and may vary slightly depending upon the region, even though many vaccines are common. These vaccines help protect children from various diseases by helping develop immunity (protection) against diseases before they come into contact with them. Vaccines are started at early age children are at increased risk for infectious diseases because their immune systems have is yet to built up the necessary defenses to fight serious infections and diseases. The paediatric vaccine market is estimated to show a significant growth at a CAGR of XX%. The growth may be attributed to the rising awareness among people regarding the importance of immunization. Increase in government and non-government funding in research and development of the vaccines will also augment the market growth for paediatric vaccines during the given time frame. However, high cost of the immunization vaccine may hamper the growth of the market during the given time frame.
This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical region. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the global paediatric Vaccine market value chain. Last step involves complete market engineering which includes analysing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the global paediatric vaccine market.
Major industry players profiled as part of the report are Serum Institute of India Pvt. Ltd., Novartis AG and GlaxoSmithKline plc among others.
Segmentation
By Type
Monovalent
Multivalent
By Technology
Live-attenuated vaccines
Inactivated vaccines
Subunit, recombinant, polysaccharide, and conjugate vaccines
Toxoid vaccines
Others
By Application
Infectious Diseases
Cancer
Allergies
By Geography
North America
United States
Canada
Others
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
China
India
Australia
South Korea
Others
This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical region. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the global paediatric Vaccine market value chain. Last step involves complete market engineering which includes analysing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the global paediatric vaccine market.
Major industry players profiled as part of the report are Serum Institute of India Pvt. Ltd., Novartis AG and GlaxoSmithKline plc among others.
Segmentation
By Type
Monovalent
Multivalent
By Technology
Live-attenuated vaccines
Inactivated vaccines
Subunit, recombinant, polysaccharide, and conjugate vaccines
Toxoid vaccines
Others
By Application
Infectious Diseases
Cancer
Allergies
By Geography
North America
United States
Canada
Others
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
China
India
Australia
South Korea
Others
1. INTRODUCTION
1.1. Market Definition
1.2. Scope of the Study
1.3. Currency
1.4. Assumptions
1.5. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
2.3. Validation
3. KEY FINDINGS OF THE STUDY
4. MARKET DYNAMICS
4.1. Drivers
4.2. Restraints
4.3. Opportunities and Market Trends
4.4. Market Segmentation
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Industry Value Chain Analysis
4.7. Industry Regulations
4.8. Scenario Analysis
5. GLOBAL PAEDIATRIC VACCINE MARKET FORECAST BY TYPE
5.1. Monovalent
5.2. Multivalent
6. GLOBAL PAEDIATRIC VACCINE MARKET FORECAST BY TECHNIQUE
6.1. Live-attenuated vaccines
6.2. Inactivated vaccines
6.3. Subunit, recombinant, polysaccharide, and conjugate vaccines
6.4. Toxoid vaccines
6.5. Others
7. GLOBAL PAEDIATRIC VACCINE MARKET FORECAST BY APPLICATION
7.1. Infectious Diseases
7.2. Cancer
7.3. Allergies
8. GLOBAL PAEDIATRIC VACCINE MARKET FORECAST BY GEOGRAPHY
8.1. North America
8.1.1. The U.S
8.1.2. Canada
8.1.3. Mexico
8.1.4. Others
8.2. South America
8.2.1. Brazil
8.2.2. Argentina
8.2.3. Others
8.3. Europe
8.3.1. U.K.
8.3.2. France
8.3.3. Germany
8.3.4. Italy
8.3.5. Others
8.4. Middle East and Africa
8.4.1. Saudi Arabia
8.4.2. UAE
8.4.3. Israel
8.4.4. Others
8.5. Asia Pacific
8.5.1. China
8.5.2. India
8.5.3. Australia
8.5.4. South Korea
8.5.5. Others
9. COMPETITIVE INTELLIGENCE
9.1. Market Share Analysis
9.2. Strategies of Key Players
9.3. Recent Investments and Deals
10. COMPANY PROFILES
10.1. GlaxoSmithKline plc
10.1.1. Overview
10.1.2. Financials
10.1.3. Product and Services
10.1.4. Recent Developments
10.2. Merck Sharp & Dohme Corp.
10.2.1. Overview
10.2.2. Financials
10.2.3. Product and Services
10.2.4. Recent Developments
10.3. Sanofi
10.3.1. Overview
10.3.2. Financials
10.3.3. Product and Services
10.3.4. Recent Developments
10.4. Pfizer Inc.
10.4.1. Overview
10.4.2. Financials
10.4.3. Product and Services
10.4.4. Recent Developments
10.5. VBI Vaccines Inc.
10.5.1. Overview
10.5.2. Financials
10.5.3. Product and Services
10.5.4. Recent Developments
10.6. Serum Institute of India Pvt. Ltd.
10.6.1. Overview
10.6.2. Financials
10.6.3. Product and Services
10.6.4. Recent Developments
10.7. AstraZeneca
10.7.1. Overview
10.7.2. Financials
10.7.3. Product and Services
10.7.4. Recent Developments
10.8. Mitsubishi Tanabe Pharma Corporation
10.8.1. Overview
10.8.2. Financials
10.8.3. Product and Services
10.8.4. Recent Developments
10.9. Novartis AG
10.9.1. Overview
10.9.2. Financials
10.9.3. Product and Services
10.9.4. Recent Developments
10.10. Seqirus (CSL Limited)
10.10.1. Overview
10.10.2. Financials
10.10.3. Product and Services
10.10.4. Recent Developments
1.1. Market Definition
1.2. Scope of the Study
1.3. Currency
1.4. Assumptions
1.5. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
2.3. Validation
3. KEY FINDINGS OF THE STUDY
4. MARKET DYNAMICS
4.1. Drivers
4.2. Restraints
4.3. Opportunities and Market Trends
4.4. Market Segmentation
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Industry Value Chain Analysis
4.7. Industry Regulations
4.8. Scenario Analysis
5. GLOBAL PAEDIATRIC VACCINE MARKET FORECAST BY TYPE
5.1. Monovalent
5.2. Multivalent
6. GLOBAL PAEDIATRIC VACCINE MARKET FORECAST BY TECHNIQUE
6.1. Live-attenuated vaccines
6.2. Inactivated vaccines
6.3. Subunit, recombinant, polysaccharide, and conjugate vaccines
6.4. Toxoid vaccines
6.5. Others
7. GLOBAL PAEDIATRIC VACCINE MARKET FORECAST BY APPLICATION
7.1. Infectious Diseases
7.2. Cancer
7.3. Allergies
8. GLOBAL PAEDIATRIC VACCINE MARKET FORECAST BY GEOGRAPHY
8.1. North America
8.1.1. The U.S
8.1.2. Canada
8.1.3. Mexico
8.1.4. Others
8.2. South America
8.2.1. Brazil
8.2.2. Argentina
8.2.3. Others
8.3. Europe
8.3.1. U.K.
8.3.2. France
8.3.3. Germany
8.3.4. Italy
8.3.5. Others
8.4. Middle East and Africa
8.4.1. Saudi Arabia
8.4.2. UAE
8.4.3. Israel
8.4.4. Others
8.5. Asia Pacific
8.5.1. China
8.5.2. India
8.5.3. Australia
8.5.4. South Korea
8.5.5. Others
9. COMPETITIVE INTELLIGENCE
9.1. Market Share Analysis
9.2. Strategies of Key Players
9.3. Recent Investments and Deals
10. COMPANY PROFILES
10.1. GlaxoSmithKline plc
10.1.1. Overview
10.1.2. Financials
10.1.3. Product and Services
10.1.4. Recent Developments
10.2. Merck Sharp & Dohme Corp.
10.2.1. Overview
10.2.2. Financials
10.2.3. Product and Services
10.2.4. Recent Developments
10.3. Sanofi
10.3.1. Overview
10.3.2. Financials
10.3.3. Product and Services
10.3.4. Recent Developments
10.4. Pfizer Inc.
10.4.1. Overview
10.4.2. Financials
10.4.3. Product and Services
10.4.4. Recent Developments
10.5. VBI Vaccines Inc.
10.5.1. Overview
10.5.2. Financials
10.5.3. Product and Services
10.5.4. Recent Developments
10.6. Serum Institute of India Pvt. Ltd.
10.6.1. Overview
10.6.2. Financials
10.6.3. Product and Services
10.6.4. Recent Developments
10.7. AstraZeneca
10.7.1. Overview
10.7.2. Financials
10.7.3. Product and Services
10.7.4. Recent Developments
10.8. Mitsubishi Tanabe Pharma Corporation
10.8.1. Overview
10.8.2. Financials
10.8.3. Product and Services
10.8.4. Recent Developments
10.9. Novartis AG
10.9.1. Overview
10.9.2. Financials
10.9.3. Product and Services
10.9.4. Recent Developments
10.10. Seqirus (CSL Limited)
10.10.1. Overview
10.10.2. Financials
10.10.3. Product and Services
10.10.4. Recent Developments
